Roche Outlines Use Of Real-World Evidence In Entrectinib NDA
Roche used its Flatiron Health oncology EHR database to generate an external control arm for pivotal single-arm data supporting the personalized medicine candidate, which has an 18 August user fee goal.
You may also be interested in...
Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment
Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.
Real-World Reluctance? Despite Guidance, Drug Developers Wary Of RWE-Based Trials
Biopharma companies are reluctant to rely on real-world evidence trials, but while uncertainty remains about how these novel studies will be accepted, US and other regulators are encouraging drug developers to take a chance – and some have taken on the challenge.
Heralding Change: Product Pipeline Advances To Watch Out For In Q3
Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.